Author: "Bartorelli, Antonio" / Publication Type: Electronic Resources - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Bartorelli, Antonio"' showing total 55 results

Start Over Author "Bartorelli, Antonio" Publication Type Electronic Resources

55 results on '"Bartorelli, Antonio"'

1. One-year outcomes after transcatheter aortic valve implantation with the latest-generation SAPIEN balloonexpandable valve : the S3U registry

Author: Cannata, Stefano, Gandolfo, Caterina, Ribichini, Flavio, Van Mieghem, Nicolas, Buccheri, Sergio, Barbanti, Marco, Berti, Sergio, Teles, Rui Campante, Bartorelli, Antonio L., Musumeci, Giuseppe, Piva, Tommaso, Nombela-Franco, Luis, La Spina, Ketty, Palmerini, Tullio, Adrichem, Rik, Esposito, Augusto, Lopes, Pedro, Olivares, Paolo, Annibali, Gianmarco, Nicolini, Elisa, Marroquin, Luis, Tamburino, Corrado, Tarantini, Giuseppe, Saia, Francesco, Cannata, Stefano, Gandolfo, Caterina, Ribichini, Flavio, Van Mieghem, Nicolas, Buccheri, Sergio, Barbanti, Marco, Berti, Sergio, Teles, Rui Campante, Bartorelli, Antonio L., Musumeci, Giuseppe, Piva, Tommaso, Nombela-Franco, Luis, La Spina, Ketty, Palmerini, Tullio, Adrichem, Rik, Esposito, Augusto, Lopes, Pedro, Olivares, Paolo, Annibali, Gianmarco, Nicolini, Elisa, Marroquin, Luis, Tamburino, Corrado, Tarantini, Giuseppe, and Saia, Francesco
Abstract: Background: Initial data about the performance of the new-generation SAPIEN 3 Ultra (S3U) valve are highly promising. However, evidence about the longer-term performance and safety of the S3U is scarce. Aims: We aimed to investigate the 1-year clinical and echocardiographic outcomes of transcatheter aortic valve implantation (TAVI) using the S3U compared with its predecessor, the SAPIEN 3 valve (S3). Methods: The SAPIEN 3 Ultra registry included consecutive patients who underwent transfemoral TAVI at 12 European centres with the S3U or S3 between October 2016 and December 2020. One-to-one propensity score (PS) matching was performed to account for differences in baseline characteristics. The primary outcomes of interest were all-cause death and the composite of all-cause death, disabling stroke and hospitalisation for heart failure at 1 year. Results: The overall study cohort encompassed 1,692 patients treated with either the S3U (n=519) or S3 (n=1,173). The PS-matched population had a total of 992 patients (496 per group). At 1 year, the rate of death from any cause was 4.9% in the S3U group and 6.3% in the S3 group (p=0.743). Similarly, there were no significant differences in the rates of the primary composite outcome (9.5% in the S3 group and 6.6% in the S3U group; p=0.162). The S3U was associated with lower rates of mild paravalvular leak (PVL) compared with the S3 (odds ratio 0.63, 95% confidence interval: 0.44 to 0.88; p<0.01). No significant differences in transprosthetic gradients were observed between the two groups. Conclusions: Compared with the S3, the S3U transcatheter heart valve was associated with similar 1-year clinical outcomes but reduced rates of mild PVL.
Published: 2023
Full Text: View/download PDF

2. Vascular Access in Patients With Peripheral Arterial Disease Undergoing TAVR: The Hostile Registry

Author: Palmerini, Tullio, Saia, Francesco, Kim, Won-Keun, Renker, Matthia, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lar, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M, Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thoma, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M, Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B, Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jona, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L, Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, Stone, Gregg W, Burzotta, Francesco (ORCID:0000-0002-6569-9401), Trani, Carlo (ORCID:0000-0001-9777-013X), Porto, Italo (ORCID:0000-0002-9854-5046), Palmerini, Tullio, Saia, Francesco, Kim, Won-Keun, Renker, Matthia, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lar, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M, Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thoma, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M, Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B, Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jona, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L, Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, Stone, Gregg W, Burzotta, Francesco (ORCID:0000-0002-6569-9401), Trani, Carlo (ORCID:0000-0001-9777-013X), and Porto, Italo (ORCID:0000-0002-9854-5046)
Abstract: Background: The optimal access route in patients with severe peripheral artery disease (PAD) undergoing transcatheter aortic valve replacement (TAVR) remains undetermined. Objectives: This study sought to compare clinical outcomes with transfemoral access (TFA), transthoracic access (TTA), and nonthoracic transalternative access (TAA) in TAVR patients with severe PAD. Methods: Patients with PAD and hostile femoral access (TFA impossible, or possible only after percutaneous treatment) undergoing TAVR at 28 international centers were included in this registry. The primary endpoint was the propensity-adjusted risk of 30-day major adverse events (MAE) defined as the composite of all-cause mortality, stroke/transient ischemic attack (TIA), or main access site-related Valve Academic Research Consortium 3 major vascular complications. Outcomes were also stratified according to the severity of PAD using a novel risk score (Hostile score). Results: Among the 1,707 patients included in the registry, 518 (30.3%) underwent TAVR with TFA after percutaneous treatment, 642 (37.6%) with TTA, and 547 (32.0%) with TAA (mostly transaxillary). Compared with TTA, both TFA (adjusted HR: 0.58; 95% CI: 0.45-0.75) and TAA (adjusted HR: 0.60; 95% CI: 0.47-0.78) were associated with lower 30-day rates of MAE, driven by fewer access site-related complications. Composite risks at 1 year were also lower with TFA and TAA compared with TTA. TFA compared with TAA was associated with lower 1-year risk of stroke/TIA (adjusted HR: 0.49; 95% CI: 0.24-0.98), a finding confined to patients with low Hostile scores (Pinteraction = 0.049). Conclusions: Among patients with PAD undergoing TAVR, both TFA and TAA were associated with lower 30-day and 1-year rates of MAE compared with TTA, but 1-year stroke/TIA rates were higher with TAA compared with TFA.
Published: 2023

3. Vascular Access in Patients With Peripheral Arterial Disease Undergoing TAVR:The Hostile Registry

Author: Palmerini, Tullio, Saia, Francesco, Kim, Won Keun, Renker, Matthias, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lars, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M., Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thomas, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M., Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B., Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jonas, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L., Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, Stone, Gregg W., Palmerini, Tullio, Saia, Francesco, Kim, Won Keun, Renker, Matthias, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lars, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M., Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thomas, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M., Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B., Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jonas, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L., Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, and Stone, Gregg W.
Abstract: Background: The optimal access route in patients with severe peripheral artery disease (PAD) undergoing transcatheter aortic valve replacement (TAVR) remains undetermined. Objectives: This study sought to compare clinical outcomes with transfemoral access (TFA), transthoracic access (TTA), and nonthoracic transalternative access (TAA) in TAVR patients with severe PAD. Methods: Patients with PAD and hostile femoral access (TFA impossible, or possible only after percutaneous treatment) undergoing TAVR at 28 international centers were included in this registry. The primary endpoint was the propensity-adjusted risk of 30-day major adverse events (MAE) defined as the composite of all-cause mortality, stroke/transient ischemic attack (TIA), or main access site–related Valve Academic Research Consortium 3 major vascular complications. Outcomes were also stratified according to the severity of PAD using a novel risk score (Hostile score). Results: Among the 1,707 patients included in the registry, 518 (30.3%) underwent TAVR with TFA after percutaneous treatment, 642 (37.6%) with TTA, and 547 (32.0%) with TAA (mostly transaxillary). Compared with TTA, both TFA (adjusted HR: 0.58; 95% CI: 0.45-0.75) and TAA (adjusted HR: 0.60; 95% CI: 0.47-0.78) were associated with lower 30-day rates of MAE, driven by fewer access site–related complications. Composite risks at 1 year were also lower with TFA and TAA compared with TTA. TFA compared with TAA was associated with lower 1-year risk of stroke/TIA (adjusted HR: 0.49; 95% CI: 0.24-0.98), a finding confined to patients with low Hostile scores (Pinteraction = 0.049). Conclusions: Among patients with PAD undergoing TAVR, both TFA and TAA were associated with lower 30-day and 1-year rates of MAE compared with TTA, but 1-year stroke/TIA rates were higher with TAA compared with TFA.
Published: 2023

4. Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement.

Author: UCL - (SLuc) Département cardiovasculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Vendramin, Igor, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria-Cristina, Corriea de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R, Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S, Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, Rodés-Cabau, Josep, UCL - (SLuc) Département cardiovasculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Vendramin, Igor, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria-Cristina, Corriea de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R, Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S, Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, and Rodés-Cabau, Josep
Abstract: Staphylococcus aureus (SA) has been extensively studied as causative microorganism of surgical prosthetic-valve infective endocarditis (IE). However, scarce evidence exists on SA IE after transcatheter aortic valve replacement (TAVR). Data were obtained from the Infectious Endocarditis After TAVR International Registry, including patients with definite IE after TAVR from 59 centres in 11 countries. Patients were divided into 2 groups according to microbiologic etiology: non-SA IE vs SA IE. SA IE was identified in 141 patients out of 573 (24.6%), methicillin-sensitive SA in most cases (115/141, 81.6%). Self-expanding valves were more common than balloon-expandable valves in patients presenting with early SA IE. Major bleeding and sepsis complicating TAVR, neurologic symptoms or systemic embolism at admission, and IE with cardiac device involvement (other than the TAVR prosthesis) were associated with SA IE (P < 0.05 for all). Among patients with IE after TAVR, the likelihood of SA IE increased from 19% in the absence of those risk factors to 84.6% if ≥ 3 risk factors were present. In-hospital (47.8% vs 26.9%; P < 0.001) and 2-year (71.5% vs 49.6%; P < 0.001) mortality rates were higher among patients with SA IE vs non-SA IE. Surgery at the time of index SA IE episode was associated with lower mortality at follow-up compared with medical therapy alone (adjusted hazard ratio 0.46, 95% CI 0.22-0.96; P = 0.038). SA IE represented approximately 25% of IE cases after TAVR and was associated with very high in-hospital and late mortality. The presence of some features determined a higher likelihood of SA IE and could help to orientate early antibiotic regimen selection. Surgery at index SA IE was associated with improved outcomes, and its role should be evaluated in future studies.
Published: 2022

5. Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation.

Author: UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Département cardiovasculaire, Panagides, Vassili, Del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Scislo, Piotr, Huczek, Zenon, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Kim, Won-Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, Brito, Fabio Sandoli de, Dato, Guglielmo Mario Actis, Rosato, Francesco, Ferreira, Maria-Cristina, de Lima, Valter Correia, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R, Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Breton, Hervé Le, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S, Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, Rodés-Cabau, Josep, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Département cardiovasculaire, Panagides, Vassili, Del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Scislo, Piotr, Huczek, Zenon, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Kim, Won-Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, Brito, Fabio Sandoli de, Dato, Guglielmo Mario Actis, Rosato, Francesco, Ferreira, Maria-Cristina, de Lima, Valter Correia, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R, Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Breton, Hervé Le, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S, Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, and Rodés-Cabau, Josep
Abstract: Scarce data exist on mitral valve (MV) infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). This multicenter study included a total of 579 patients with a diagnosis of definite IE after TAVI from the IE after TAVI International Registry and aimed to evaluate the incidence, characteristics, management, and outcomes of MV-IE after TAVI. A total of 86 patients (14.9%) had MV-IE. These patients were compared with 284 patients (49.1%) with involvement of the transcatheter heart valve (THV) only. Two factors were found to be associated with MV-IE: the use of self-expanding valves (adjusted odds ratio 2.49, 95% confidence interval [CI] 1.23 to 5.07, p = 0.012), and the presence of an aortic regurgitation ≥2 at discharge (adjusted odds ratio 3.33; 95% CI 1.43 to 7.73, p <0.01). There were no differences in IE timing and causative microorganisms between groups, but surgical management was significantly lower in patients with MV-IE (6.0%, vs 21.6% in patients with THV-IE, p = 0.001). All-cause mortality rates at 2-year follow-up were high and similar between patients with MV-IE (51.4%, 95% CI 39.8 to 64.1) and patients with THV-IE (51.5%, 95% CI 45.4 to 58.0) (log-rank p = 0.295). The factors independently associated with increased mortality risk in patients with MV-IE were the occurrence of heart failure (adjusted p <0.001) and septic shock (adjusted p <0.01) during the index hospitalization. One of 6 IE episodes after TAVI is localized on the MV. The implantation of a self-expanding THV and the presence of an aortic regurgitation ≥2 at discharge were associated with MV-IE. Patients with MV-IE were rarely operated on and had a poor prognosis at 2-year follow-up.
Published: 2022

6. Surgical Treatment of Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation.

Author: UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Département cardiovasculaire, Mangner, Norman, del Val, David, Abdel-Wahab, Mohamed, Crusius, Lisa, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Kim, Won-Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria-Cristina, Correia de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R, Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S, Boukhris, Marouane, Gervais, Philippe, Côté, Mélanie, Holzhey, David, Linke, Axel, Rodés-Cabau, Josep, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Département cardiovasculaire, Mangner, Norman, del Val, David, Abdel-Wahab, Mohamed, Crusius, Lisa, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Kim, Won-Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria-Cristina, Correia de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R, Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S, Boukhris, Marouane, Gervais, Philippe, Côté, Mélanie, Holzhey, David, Linke, Axel, and Rodés-Cabau, Josep
Abstract: The optimal treatment of patients developing infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI) is uncertain. The goal of this study was to investigate the clinical characteristics and outcomes of patients with TAVI-IE treated with cardiac surgery and antibiotics (IE-CS) compared with patients treated with antibiotics alone (IE-AB). Crude and inverse probability of treatment weighting analyses were applied for the treatment effect of cardiac surgery vs medical therapy on 1-year all-cause mortality in patients with definite TAVI-IE. The study used data from the Infectious Endocarditis after TAVI International Registry. Among 584 patients, 111 patients (19%) were treated with IE-CS and 473 patients (81%) with IE-AB. Compared with IE-AB, IE-CS was not associated with a lower in-hospital mortality (HR: 0.85; 95% CI: 0.58-1.25) and 1-year all-cause mortality (HR: 0.88; 95% CI: 0.64-1.22) in the crude cohort. After adjusting for selection and immortal time bias, IE-CS compared with IE-AB was also not associated with lower mortality rates for in-hospital mortality (HR: 0.92; 95% CI: 0.80-1.05) and 1-year all-cause mortality (HR: 0.95; 95% CI: 0.84-1.07). Results remained similar when patients with and without TAVI prosthesis involvement were analyzed separately. Predictors for in-hospital and 1-year all-cause mortality included logistic EuroSCORE I, Staphylococcus aureus, acute renal failure, persistent bacteremia, and septic shock. In this registry, the majority of patients with TAVI-IE were treated with antibiotics alone. Cardiac surgery was not associated with an improved all-cause in-hospital or 1-year mortality. The high mortality of patients with TAVI-IE was strongly linked to patients' characteristics, pathogen, and IE-related complications.
Published: 2022

7. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis The Task Force for the management of COVID-19 of the European Society of Cardiology

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities. [GRAPHICS] .
Published: 2022

8. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

9. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

10. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities. [GRAPHICS] .
Published: 2022

11. Prosthesis-patient mismatch following transcatheter aortic valve replacement for degenerated transcatheter aortic valves:the TRANSIT-PPM international project

Author: Testa, Luca, Casenghi, Matteo, Criscione, Enrico, Van Mieghem, Nicolas M., Tchétché, Didier, Asgar, Anita W., De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P., Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Brinkmann, Christina, van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Agnifili, Mauro, Rubbio, Antonio Popolo, Squillace, Mattia, Oreglia, Jacopo, Tanja, Rudolph, McCabe, James M., Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Zoccai, Giuseppe Biondi, Sondergaard, Lars, Bedogni, Francesco, Testa, Luca, Casenghi, Matteo, Criscione, Enrico, Van Mieghem, Nicolas M., Tchétché, Didier, Asgar, Anita W., De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P., Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Brinkmann, Christina, van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Agnifili, Mauro, Rubbio, Antonio Popolo, Squillace, Mattia, Oreglia, Jacopo, Tanja, Rudolph, McCabe, James M., Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Zoccai, Giuseppe Biondi, Sondergaard, Lars, and Bedogni, Francesco
Abstract: Background: A severe prosthesis-patient mismatch (PPM) is associated with adverse outcomes following transcatheter aortic valve replacement (TAVR) for de novo aortic stenosis or a failed surgical bioprosthesis. The impact of severe PPM in patients undergoing TAV-in-TAVR is unknown. Aim: We sought to investigate the incidence and 1-year outcomes of different grades of PPM in patients undergoing TAV-in-TAVR. Materials and methods: The TRANSIT-PPM is an international registry, including cases of degenerated TAVR treated with a second TAVR. PPM severity, as well as in-hospital, 30-day, and 1-year outcomes were defined according to the Valve Academic Research Consortium-3 (VARC-3) criteria. Results: Among 28 centers, 155 patients were included. Severe PPM was found in 6.5% of patients, whereas moderate PPM was found in 14.2% of patients. The rate of severe PPM was higher in patients who underwent TAV-in-TAVR with a second supra-annular self-expanding (S-SE) TAVR (10%, p = 0.04). Specifically, the rate of severe PPM was significantly higher among cases of a SE TAVR implanted into a balloon-expandable (BE) device (19%, p = 0.003). At 1-year follow-up, the rate of all-cause mortality, and the rate of patients in the New York Heart Association (NYHA) class III/IV were significantly higher in the cohort of patients with severe PPM (p = 0.016 and p = 0.0001, respectively). Almost all the patients with a severe PPM after the first TAVR had a failed < 23 mm BE transcatheter heart valve (THV): the treatment with an S-SE resolved the severe PPM in the majority of the cases. Conclusion: After TAV-in-TAVR, in a fifth of the cases, a moderate or severe PPM occurred. A severe PPM is associated with an increased 1-year all-cause mortality. Clinical trial registration: [https://clinicaltrials.gov], identifier [NCT04500964].
Published: 2022

12. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic:part 2-care pathways, treatment, and follow-up

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L, Baumbach, Andreas, Behr, Elijah R, Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J, Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A, Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M, Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L, Baumbach, Andreas, Behr, Elijah R, Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J, Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A, Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M, Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, and Price, Susanna
Abstract: Aims: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

13. Prosthesis-patient mismatch following transcatheter aortic valve replacement for degenerated transcatheter aortic valves:the TRANSIT-PPM international project

Author: Testa, Luca, Casenghi, Matteo, Criscione, Enrico, Van Mieghem, Nicolas M., Tchétché, Didier, Asgar, Anita W., De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P., Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Brinkmann, Christina, van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Agnifili, Mauro, Rubbio, Antonio Popolo, Squillace, Mattia, Oreglia, Jacopo, Tanja, Rudolph, McCabe, James M., Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Zoccai, Giuseppe Biondi, Sondergaard, Lars, Bedogni, Francesco, Testa, Luca, Casenghi, Matteo, Criscione, Enrico, Van Mieghem, Nicolas M., Tchétché, Didier, Asgar, Anita W., De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P., Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Brinkmann, Christina, van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Agnifili, Mauro, Rubbio, Antonio Popolo, Squillace, Mattia, Oreglia, Jacopo, Tanja, Rudolph, McCabe, James M., Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Zoccai, Giuseppe Biondi, Sondergaard, Lars, and Bedogni, Francesco
Abstract: Background: A severe prosthesis-patient mismatch (PPM) is associated with adverse outcomes following transcatheter aortic valve replacement (TAVR) for de novo aortic stenosis or a failed surgical bioprosthesis. The impact of severe PPM in patients undergoing TAV-in-TAVR is unknown. Aim: We sought to investigate the incidence and 1-year outcomes of different grades of PPM in patients undergoing TAV-in-TAVR. Materials and methods: The TRANSIT-PPM is an international registry, including cases of degenerated TAVR treated with a second TAVR. PPM severity, as well as in-hospital, 30-day, and 1-year outcomes were defined according to the Valve Academic Research Consortium-3 (VARC-3) criteria. Results: Among 28 centers, 155 patients were included. Severe PPM was found in 6.5% of patients, whereas moderate PPM was found in 14.2% of patients. The rate of severe PPM was higher in patients who underwent TAV-in-TAVR with a second supra-annular self-expanding (S-SE) TAVR (10%, p = 0.04). Specifically, the rate of severe PPM was significantly higher among cases of a SE TAVR implanted into a balloon-expandable (BE) device (19%, p = 0.003). At 1-year follow-up, the rate of all-cause mortality, and the rate of patients in the New York Heart Association (NYHA) class III/IV were significantly higher in the cohort of patients with severe PPM (p = 0.016 and p = 0.0001, respectively). Almost all the patients with a severe PPM after the first TAVR had a failed < 23 mm BE transcatheter heart valve (THV): the treatment with an S-SE resolved the severe PPM in the majority of the cases. Conclusion: After TAV-in-TAVR, in a fifth of the cases, a moderate or severe PPM occurred. A severe PPM is associated with an increased 1-year all-cause mortality. Clinical trial registration: [https://clinicaltrials.gov], identifier [NCT04500964].
Published: 2022

14. Perivalvular Extension of Infective Endocarditis After Transcatheter Aortic Valve Replacement

Author: Panagides, Vassili, Del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N., Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C., Testa, Luca, Kim, Won Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L., Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C., Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B., Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria Cristina, Correia de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G., Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, Rodés-Cabau, Josep, Panagides, Vassili, Del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N., Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C., Testa, Luca, Kim, Won Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L., Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C., Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B., Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria Cristina, Correia de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G., Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, and Rodés-Cabau, Josep
Abstract: BACKGROUND: Infective endocarditis (IE) following transcatheter aortic valve replacement (TAVR) has been associated with a dismal prognosis. However, scarce data exist on IE perivalvular extension (PEE) in such patients. METHODS: This multicenter study included 579 patients who had the diagnosis of definite IE at a median of 171 (53-421) days following TAVR. PEE was defined as the presence of an intracardiac abscess, pseudoaneurysm, or fistula. RESULTS: A total of 105 patients (18.1%) were diagnosed with PEE (perivalvular abscess, pseudoaneurysm, fistula, or a combination in 87, 7, 7, and 4 patients, respectively). A history of chronic kidney disease (adjusted odds ratio [ORadj], 2.08; 95% confidence interval [CI]: 1.27-3.41; P = .003) and IE secondary to coagulase-negative staphylococci (ORadj, 2.71; 95% CI: 1.57-4.69; P < .001) were associated with an increased risk of PEE. Surgery was performed at index IE episode in 34 patients (32.4%) with PEE (vs 15.2% in patients without PEE, P < .001). In-hospital and 2-year mortality rates among PEE-IE patients were 36.5% and 69.4%, respectively. Factors independently associated with an increased mortality were the occurrence of other complications (stroke post-TAVR, acute renal failure, septic shock) and the lack of surgery at index IE hospitalization (padj < 0.05 for all). CONCLUSIONS: PEE occurred in about one-fifth of IE post-TAVR patients, with the presence of coagulase-negative staphylococci and chronic kidney disease determining an increased risk. Patients with PEE-IE exhibited high early and late mortality rates, and surgery during IE hospitalization seemed to be associated with better outcomes.
Published: 2022

15. Perivalvular Extension of Infective Endocarditis After Transcatheter Aortic Valve Replacement

Author: Panagides, Vassili, Del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N., Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C., Testa, Luca, Kim, Won Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L., Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C., Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B., Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria Cristina, Correia de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G., Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, Rodés-Cabau, Josep, Panagides, Vassili, Del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N., Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C., Testa, Luca, Kim, Won Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L., Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C., Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B., Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria Cristina, Correia de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G., Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, and Rodés-Cabau, Josep
Abstract: BACKGROUND: Infective endocarditis (IE) following transcatheter aortic valve replacement (TAVR) has been associated with a dismal prognosis. However, scarce data exist on IE perivalvular extension (PEE) in such patients. METHODS: This multicenter study included 579 patients who had the diagnosis of definite IE at a median of 171 (53-421) days following TAVR. PEE was defined as the presence of an intracardiac abscess, pseudoaneurysm, or fistula. RESULTS: A total of 105 patients (18.1%) were diagnosed with PEE (perivalvular abscess, pseudoaneurysm, fistula, or a combination in 87, 7, 7, and 4 patients, respectively). A history of chronic kidney disease (adjusted odds ratio [ORadj], 2.08; 95% confidence interval [CI]: 1.27-3.41; P = .003) and IE secondary to coagulase-negative staphylococci (ORadj, 2.71; 95% CI: 1.57-4.69; P < .001) were associated with an increased risk of PEE. Surgery was performed at index IE episode in 34 patients (32.4%) with PEE (vs 15.2% in patients without PEE, P < .001). In-hospital and 2-year mortality rates among PEE-IE patients were 36.5% and 69.4%, respectively. Factors independently associated with an increased mortality were the occurrence of other complications (stroke post-TAVR, acute renal failure, septic shock) and the lack of surgery at index IE hospitalization (padj < 0.05 for all). CONCLUSIONS: PEE occurred in about one-fifth of IE post-TAVR patients, with the presence of coagulase-negative staphylococci and chronic kidney disease determining an increased risk. Patients with PEE-IE exhibited high early and late mortality rates, and surgery during IE hospitalization seemed to be associated with better outcomes.
Published: 2022

16. Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement

Author: del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Vendramin, Igor, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria-Cristina, Corriea de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, Rodés-Cabau, Josep, del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Vendramin, Igor, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria-Cristina, Corriea de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, and Rodés-Cabau, Josep
Abstract: Background: Staphylococcus aureus (SA) has been extensively studied as causative microorganism of surgical prosthetic-valve infective endocarditis (IE). However, scarce evidence exists on SA IE after transcatheter aortic valve replacement (TAVR). Methods: Data were obtained from the Infectious Endocarditis After TAVR International Registry, including patients with definite IE after TAVR from 59 centres in 11 countries. Patients were divided into 2 groups according to microbiologic etiology: non-SA IE vs SA IE. Results: SA IE was identified in 141 patients out of 573 (24.6%), methicillin-sensitive SA in most cases (115/141, 81.6%). Self-expanding valves were more common than balloon-expandable valves in patients presenting with early SA IE. Major bleeding and sepsis complicating TAVR, neurologic symptoms or systemic embolism at admission, and IE with cardiac device involvement (other than the TAVR prosthesis) were associated with SA IE (P < 0.05 for all). Among patients with IE after TAVR, the likelihood of SA IE increased from 19% in the absence of those risk factors to 84.6% if ≥ 3 risk factors were present. In-hospital (47.8% vs 26.9%; P < 0.001) and 2-year (71.5% vs 49.6%; P < 0.001) mortality rates were higher among patients with SA IE vs non-SA IE. Surgery at the time of index SA IE episode was associated with lower mortality at follow-up compared with medical therapy alone (adjusted hazard ratio 0.46, 95% CI 0.22-0.96; P = 0.038). Conclusions: SA IE represented approximately 25% of IE cases after TAVR and was associated with very high in-hospital and late mortality. The presence of some features determined a higher likelihood of SA IE and could help to orientate early antibiotic regimen selection. Surgery at index SA IE was associated with improved outcomes, and its role should be evaluated in future studies.
Published: 2022

17. Surgical Treatment of Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation

Author: Mangner, Norman, del Val, David, Abdel-Wahab, Mohamed, Crusius, Lisa, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N., Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C., Testa, Luca, Kim, Won-Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L., Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C., Lisko, John, Gutierrez-Ibanes, Enrique, Serra, Vicenc, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frederic, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B., Mangione, Jose Armando, de Brito, Fabio Sandoli, Dato, Guglielmo Mario Actis, Rosato, Francesco, Ferreira, Maria-Cristina, de Lima, Valter Correia, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Sondergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Herve, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G., Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Cote, Melanie, Holzhey, David, Linke, Axel, Rodes-Cabau, Josep, Mangner, Norman, del Val, David, Abdel-Wahab, Mohamed, Crusius, Lisa, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N., Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C., Testa, Luca, Kim, Won-Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L., Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C., Lisko, John, Gutierrez-Ibanes, Enrique, Serra, Vicenc, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frederic, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B., Mangione, Jose Armando, de Brito, Fabio Sandoli, Dato, Guglielmo Mario Actis, Rosato, Francesco, Ferreira, Maria-Cristina, de Lima, Valter Correia, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Sondergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Herve, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G., Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Cote, Melanie, Holzhey, David, Linke, Axel, and Rodes-Cabau, Josep
Abstract: BACKGROUND The optimal treatment of patients developing infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI) is uncertain.OBJECTIVES The goal of this study was to investigate the clinical characteristics and outcomes of patients with TAVI-IE treated with cardiac surgery and antibiotics (IE-CS) compared with patients treated with antibiotics alone (IE-AB).METHODS Crude and inverse probability of treatment weighting analyses were applied for the treatment effect of cardiac surgery vs medical therapy on 1-year all-cause mortality in patients with definite TAVI-IE. The study used data from the Infectious Endocarditis after TAVI International Registry.RESULTS Among 584 patients, 111 patients (19%) were treated with IE-CS and 473 patients (81%) with IE-AB. Compared with IE-AB, IE-CS was not associated with a lower in-hospital mortality (HRunadj: 0.85; 95% CI: 0.58-1.25) and 1-year all-cause mortality (HRunadj: 0.88; 95% CI: 0.64-1.22) in the crude cohort. After adjusting for selection and immortal time bias, IE-CS compared with IE-AB was also not associated with lower mortality rates for in-hospital mortality (HRadj: 0.92; 95% CI: 0.80-1.05) and 1-year all-cause mortality (HRadj: 0.95; 95% CI: 0.84-1.07). Results remained similar when patients with and without TAVI prosthesis involvement were analyzed separately. Predictors for in-hospital and 1-year all-cause mortality included logistic EuroSCORE I, Staphylococcus aureus, acute renal failure, persistent bacteremia, and septic shock.CONCLUSIONS In this registry, the majority of patients with TAVI-IE were treated with antibiotics alone. Cardiac surgery was not associated with an improved all-cause in-hospital or 1-year mortality. The high mortality of patients with TAVI-IE was strongly linked to patients' characteristics, pathogen, and IE-related complications. (C) 2022 by the American College of Cardiology Foundation.
Published: 2022

18. Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation

Author: Panagides, Vassili, del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Scislo, Piotr, Huczek, Zenon, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Kim, Won-Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, de Brito, Fabio Sandoli, Dato, Guglielmo Mario Actis, Rosato, Francesco, Ferreira, Maria-Cristina, de Lima, Valter Correia, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Breton, Hervé Le, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, Rodés-Cabau, Josep, Panagides, Vassili, del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Scislo, Piotr, Huczek, Zenon, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Kim, Won-Keun, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, de Brito, Fabio Sandoli, Dato, Guglielmo Mario Actis, Rosato, Francesco, Ferreira, Maria-Cristina, de Lima, Valter Correia, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Breton, Hervé Le, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, and Rodés-Cabau, Josep
Abstract: Scarce data exist on mitral valve (MV) infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). This multicenter study included a total of 579 patients with a diagnosis of definite IE after TAVI from the IE after TAVI International Registry and aimed to evaluate the incidence, characteristics, management, and outcomes of MV-IE after TAVI. A total of 86 patients (14.9%) had MV-IE. These patients were compared with 284 patients (49.1%) with involvement of the transcatheter heart valve (THV) only. Two factors were found to be associated with MV-IE: the use of self-expanding valves (adjusted odds ratio 2.49, 95% confidence interval [CI] 1.23 to 5.07, p = 0.012), and the presence of an aortic regurgitation ≥2 at discharge (adjusted odds ratio 3.33; 95% CI 1.43 to 7.73, p <0.01). There were no differences in IE timing and causative microorganisms between groups, but surgical management was significantly lower in patients with MV-IE (6.0%, vs 21.6% in patients with THV-IE, p = 0.001). All-cause mortality rates at 2-year follow-up were high and similar between patients with MV-IE (51.4%, 95% CI 39.8 to 64.1) and patients with THV-IE (51.5%, 95% CI 45.4 to 58.0) (log-rank p = 0.295). The factors independently associated with increased mortality risk in patients with MV-IE were the occurrence of heart failure (adjusted p <0.001) and septic shock (adjusted p <0.01) during the index hospitalization. One of 6 IE episodes after TAVI is localized on the MV. The implantation of a self-expanding THV and the presence of an aortic regurgitation ≥2 at discharge were associated with MV-IE. Patients with MV-IE were rarely operated on and had a poor prognosis at 2-year follow-up.
Published: 2022

19. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic:part 1 - epidemiology, pathophysiology, and diagnosis

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean Philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean Philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

20. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L, Baumbach, Andreas, Behr, Elijah R, Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-juanatey, José R, Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J, Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A, Konstantinides, Stavros V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M, Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R, Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M, Wilde, Arthur A, Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L, Baumbach, Andreas, Behr, Elijah R, Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-juanatey, José R, Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J, Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A, Konstantinides, Stavros V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M, Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R, Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M, Wilde, Arthur A, and Williams, Bryan
Abstract: Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

21. Prosthesis-patient mismatch following transcatheter aortic valve replacement for degenerated transcatheter aortic valves:the TRANSIT-PPM international project

Author: Testa, Luca, Casenghi, Matteo, Criscione, Enrico, Van Mieghem, Nicolas M., Tchétché, Didier, Asgar, Anita W., De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P., Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Brinkmann, Christina, van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Agnifili, Mauro, Rubbio, Antonio Popolo, Squillace, Mattia, Oreglia, Jacopo, Tanja, Rudolph, McCabe, James M., Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Zoccai, Giuseppe Biondi, Sondergaard, Lars, Bedogni, Francesco, Testa, Luca, Casenghi, Matteo, Criscione, Enrico, Van Mieghem, Nicolas M., Tchétché, Didier, Asgar, Anita W., De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P., Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Brinkmann, Christina, van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Agnifili, Mauro, Rubbio, Antonio Popolo, Squillace, Mattia, Oreglia, Jacopo, Tanja, Rudolph, McCabe, James M., Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Zoccai, Giuseppe Biondi, Sondergaard, Lars, and Bedogni, Francesco
Abstract: Background: A severe prosthesis-patient mismatch (PPM) is associated with adverse outcomes following transcatheter aortic valve replacement (TAVR) for de novo aortic stenosis or a failed surgical bioprosthesis. The impact of severe PPM in patients undergoing TAV-in-TAVR is unknown. Aim: We sought to investigate the incidence and 1-year outcomes of different grades of PPM in patients undergoing TAV-in-TAVR. Materials and methods: The TRANSIT-PPM is an international registry, including cases of degenerated TAVR treated with a second TAVR. PPM severity, as well as in-hospital, 30-day, and 1-year outcomes were defined according to the Valve Academic Research Consortium-3 (VARC-3) criteria. Results: Among 28 centers, 155 patients were included. Severe PPM was found in 6.5% of patients, whereas moderate PPM was found in 14.2% of patients. The rate of severe PPM was higher in patients who underwent TAV-in-TAVR with a second supra-annular self-expanding (S-SE) TAVR (10%, p = 0.04). Specifically, the rate of severe PPM was significantly higher among cases of a SE TAVR implanted into a balloon-expandable (BE) device (19%, p = 0.003). At 1-year follow-up, the rate of all-cause mortality, and the rate of patients in the New York Heart Association (NYHA) class III/IV were significantly higher in the cohort of patients with severe PPM (p = 0.016 and p = 0.0001, respectively). Almost all the patients with a severe PPM after the first TAVR had a failed < 23 mm BE transcatheter heart valve (THV): the treatment with an S-SE resolved the severe PPM in the majority of the cases. Conclusion: After TAV-in-TAVR, in a fifth of the cases, a moderate or severe PPM occurred. A severe PPM is associated with an increased 1-year all-cause mortality. Clinical trial registration: [https://clinicaltrials.gov], identifier [NCT04500964].
Published: 2022

22. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic:part 1 - epidemiology, pathophysiology, and diagnosis

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean Philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean Philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

23. Precision medicine versus standard of care for patients with myocardial infarction with non-obstructive coronary arteries (MINOCA): rationale and design of the multicentre, randomised PROMISE trial

Author: Montone, Rocco Antonio, Cosentino, Nicola, Graziani, Francesca, Gorla, Riccardo, Del Buono, Marco Giuseppe, La Vecchia, Giulia, Rinaldi, Riccardo, Marenzi, Giancarlo, Bartorelli, Antonio L, De Marco, Federico, Testa, Luca, Bedogni, Francesco, Trani, Carlo, Liuzzo, Giovanna, Niccoli, Giampaolo, Crea, Filippo, Graziani, Francesca (ORCID:0000-0002-4520-5689), Trani, Carlo (ORCID:0000-0001-9777-013X), Liuzzo, Giovanna (ORCID:0000-0002-5714-0907), Niccoli, Giampaolo (ORCID:0000-0002-3187-6262), Crea, Filippo (ORCID:0000-0001-9404-8846), Montone, Rocco Antonio, Cosentino, Nicola, Graziani, Francesca, Gorla, Riccardo, Del Buono, Marco Giuseppe, La Vecchia, Giulia, Rinaldi, Riccardo, Marenzi, Giancarlo, Bartorelli, Antonio L, De Marco, Federico, Testa, Luca, Bedogni, Francesco, Trani, Carlo, Liuzzo, Giovanna, Niccoli, Giampaolo, Crea, Filippo, Graziani, Francesca (ORCID:0000-0002-4520-5689), Trani, Carlo (ORCID:0000-0001-9777-013X), Liuzzo, Giovanna (ORCID:0000-0002-5714-0907), Niccoli, Giampaolo (ORCID:0000-0002-3187-6262), and Crea, Filippo (ORCID:0000-0001-9404-8846)
Abstract: N/A
Published: 2022

24. Prosthesis-patient mismatch following transcatheter aortic valve replacement for degenerated transcatheter aortic valves: the TRANSIT-PPM international project

Author: Testa, Luca, Casenghi, Matteo, Criscione, Enrico, Van Mieghem, Nicolas M, Tchétché, Didier, Asgar, Anita W, De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P, Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Brinkmann, Christina, van Royen, Niel, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Agnifili, Mauro, Rubbio, Antonio Popolo, Squillace, Mattia, Oreglia, Jacopo, Tanja, Rudolph, Mccabe, James M, Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Zoccai, Giuseppe Biondi, Sondergaard, Lar, Bedogni, Francesco, Trani, Carlo (ORCID:0000-0001-9777-013X), Testa, Luca, Casenghi, Matteo, Criscione, Enrico, Van Mieghem, Nicolas M, Tchétché, Didier, Asgar, Anita W, De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P, Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Brinkmann, Christina, van Royen, Niel, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Agnifili, Mauro, Rubbio, Antonio Popolo, Squillace, Mattia, Oreglia, Jacopo, Tanja, Rudolph, Mccabe, James M, Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Zoccai, Giuseppe Biondi, Sondergaard, Lar, Bedogni, Francesco, and Trani, Carlo (ORCID:0000-0001-9777-013X)
Abstract: Background: A severe prosthesis-patient mismatch (PPM) is associated with adverse outcomes following transcatheter aortic valve replacement (TAVR) for de novo aortic stenosis or a failed surgical bioprosthesis. The impact of severe PPM in patients undergoing TAV-in-TAVR is unknown. Aim: We sought to investigate the incidence and 1-year outcomes of different grades of PPM in patients undergoing TAV-in-TAVR. Materials and methods: The TRANSIT-PPM is an international registry, including cases of degenerated TAVR treated with a second TAVR. PPM severity, as well as in-hospital, 30-day, and 1-year outcomes were defined according to the Valve Academic Research Consortium-3 (VARC-3) criteria. Results: Among 28 centers, 155 patients were included. Severe PPM was found in 6.5% of patients, whereas moderate PPM was found in 14.2% of patients. The rate of severe PPM was higher in patients who underwent TAV-in-TAVR with a second supra-annular self-expanding (S-SE) TAVR (10%, p = 0.04). Specifically, the rate of severe PPM was significantly higher among cases of a SE TAVR implanted into a balloon-expandable (BE) device (19%, p = 0.003). At 1-year follow-up, the rate of all-cause mortality, and the rate of patients in the New York Heart Association (NYHA) class III/IV were significantly higher in the cohort of patients with severe PPM (p = 0.016 and p = 0.0001, respectively). Almost all the patients with a severe PPM after the first TAVR had a failed < 23 mm BE transcatheter heart valve (THV): the treatment with an S-SE resolved the severe PPM in the majority of the cases. Conclusion: After TAV-in-TAVR, in a fifth of the cases, a moderate or severe PPM occurred. A severe PPM is associated with an increased 1-year all-cause mortality.
Published: 2022

25. Impact of coronary calcification assessed by coronary CT angiography on treatment decision in patients with three-vessel CAD:insights from SYNTAX III trial

Author: Andreini, Daniele, Takahashi, Kuniaki, Mushtaq, Saima, Conte, Edoardo, Modolo, Rodrigo, Sonck, Jeroen, De Mey, Johan, Ravagnani, Paolo, Schoors, Danny, Maisano, Francesco, Kaufmann, Philipp, Lindeboom, Wietze, Morel, Marie Angele, Doenst, Torsten, Teichgräber, Ulf, Pontone, Gianluca, Pompilio, Giulio, Bartorelli, Antonio, Onuma, Yoshinobu, Serruys, Patrick W., Andreini, Daniele, Takahashi, Kuniaki, Mushtaq, Saima, Conte, Edoardo, Modolo, Rodrigo, Sonck, Jeroen, De Mey, Johan, Ravagnani, Paolo, Schoors, Danny, Maisano, Francesco, Kaufmann, Philipp, Lindeboom, Wietze, Morel, Marie Angele, Doenst, Torsten, Teichgräber, Ulf, Pontone, Gianluca, Pompilio, Giulio, Bartorelli, Antonio, Onuma, Yoshinobu, and Serruys, Patrick W.
Abstract: OBJECTIVES: The aim of this study was to determine Syntax scores based on coronary computed tomography angiography (CCTA) and invasive coronary angiography (ICA) and to assess whether heavy coronary calcification significantly limits the CCTA evaluation and the impact of severe calcification on heart team's treatment decision and procedural planning in patients with three-vessel coronary artery disease (CAD) with or without left main disease. METHODS: SYNTAX III was a multicentre, international study that included patients with three-vessel CAD with or without left main disease. The heart teams were randomized to either assess coronary arteries with coronary CCTA or ICA. We stratified the patients based on the presence of at least 1 lesion with heavy calcification defined as arc of calcium >180° within the lesion using CCTA. Agreement on the anatomical SYNTAX score and treatment decision was compared between patients with and without heavy calcifications. RESULTS: Overall, 222 patients with available CCTA and ICA were included in this trial subanalysis (104 with heavy calcification, 118 without heavy calcification). The mean difference in the anatomical SYNTAX score (CCTA derived-ICA derived) was lower in patients without heavy calcifications [mean (-1.96 SD; +1.96 SD) = 1.5 (-19.3; 22.4) vs 5.9 (-17.5; +29.3), P = 0.004]. The agreement on treatment decision did not differ between patients with (Cohen's kappa 0.79) or without coronary calcifications (Cohen's kappa 0.84). The agreement on the treatment planning did not differ between patients with (concordance 80.3%) or without coronary calcifications (concordance 82.8%). CONCLUSIONS: An overall good correlation between CCTA- and ICA-derived Syntax score was found. The presence of heavy coronary calcification moderately influenced the agreement between CCTA and ICA on the anatomical SYNTAX score. However, agreement on the treatment decision and planning was high and irrespective of the presence of calcified les
Published: 2022

26. Prosthesis-patient mismatch following transcatheter aortic valve replacement for degenerated transcatheter aortic valves: the TRANSIT-PPM international project

Author: Team Medisch, Circulatory Health, Testa, Luca, Casenghi, Matteo, Criscione, Enrico, Van Mieghem, Nicolas M, Tchétché, Didier, Asgar, Anita W, De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P, Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Brinkmann, Christina, van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Agnifili, Mauro, Rubbio, Antonio Popolo, Squillace, Mattia, Oreglia, Jacopo, Tanja, Rudolph, McCabe, James M, Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Zoccai, Giuseppe Biondi, Sondergaard, Lars, Bedogni, Francesco, Team Medisch, Circulatory Health, Testa, Luca, Casenghi, Matteo, Criscione, Enrico, Van Mieghem, Nicolas M, Tchétché, Didier, Asgar, Anita W, De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P, Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Brinkmann, Christina, van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Agnifili, Mauro, Rubbio, Antonio Popolo, Squillace, Mattia, Oreglia, Jacopo, Tanja, Rudolph, McCabe, James M, Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Zoccai, Giuseppe Biondi, Sondergaard, Lars, and Bedogni, Francesco
Published: 2022

27. Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement

Author: del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Vendramin, Igor, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria-Cristina, Corriea de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, Rodés-Cabau, Josep, del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Vendramin, Igor, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria-Cristina, Corriea de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, and Rodés-Cabau, Josep
Abstract: Background: Staphylococcus aureus (SA) has been extensively studied as causative microorganism of surgical prosthetic-valve infective endocarditis (IE). However, scarce evidence exists on SA IE after transcatheter aortic valve replacement (TAVR). Methods: Data were obtained from the Infectious Endocarditis After TAVR International Registry, including patients with definite IE after TAVR from 59 centres in 11 countries. Patients were divided into 2 groups according to microbiologic etiology: non-SA IE vs SA IE. Results: SA IE was identified in 141 patients out of 573 (24.6%), methicillin-sensitive SA in most cases (115/141, 81.6%). Self-expanding valves were more common than balloon-expandable valves in patients presenting with early SA IE. Major bleeding and sepsis complicating TAVR, neurologic symptoms or systemic embolism at admission, and IE with cardiac device involvement (other than the TAVR prosthesis) were associated with SA IE (P < 0.05 for all). Among patients with IE after TAVR, the likelihood of SA IE increased from 19% in the absence of those risk factors to 84.6% if ≥ 3 risk factors were present. In-hospital (47.8% vs 26.9%; P < 0.001) and 2-year (71.5% vs 49.6%; P < 0.001) mortality rates were higher among patients with SA IE vs non-SA IE. Surgery at the time of index SA IE episode was associated with lower mortality at follow-up compared with medical therapy alone (adjusted hazard ratio 0.46, 95% CI 0.22-0.96; P = 0.038). Conclusions: SA IE represented approximately 25% of IE cases after TAVR and was associated with very high in-hospital and late mortality. The presence of some features determined a higher likelihood of SA IE and could help to orientate early antibiotic regimen selection. Surgery at index SA IE was associated with improved outcomes, and its role should be evaluated in future studies.
Published: 2022

28. Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement.

Author: UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Département cardiovasculaire, Del Val, David, Abdel-Wahab, Mohamed, Linke, Axel, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Antonio, Herrmann, Howard C, Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, de Brito, Fabio Sandoli, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria-Cristina, Lima, Valter Correa, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S, Boukhris, Marouane, Mangner, Norman, Crusius, Lisa, Holzhey, David, Rodés-Cabau, Josep, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Département cardiovasculaire, Del Val, David, Abdel-Wahab, Mohamed, Linke, Axel, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Antonio, Herrmann, Howard C, Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C, Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Barbanti, Marco, Masson, Jean-Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B, Mangione, Jose Armando, de Brito, Fabio Sandoli, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria-Cristina, Lima, Valter Correa, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G, Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S, Boukhris, Marouane, Mangner, Norman, Crusius, Lisa, Holzhey, David, and Rodés-Cabau, Josep
Abstract: Procedural improvements combined with the contemporary clinical profile of patients undergoing transcatheter aortic valve replacement (TAVR) may have influenced the incidence and outcomes of infective endocarditis (IE) following TAVR. We aimed to determine the temporal trends, characteristics, and outcomes of IE post-TAVR. Observational study including 552 patients presenting definite IE post-TAVR. Patients were divided in 2 groups according to the timing of TAVR (historical cohort [HC]: before 2014; contemporary cohort [CC]: after 2014). Overall incidence rates of IE were similar in both cohorts (CC vs HC: 5.45 vs 6.52 per 1000 person-years; P = .12), but the rate of early IE was lower in the CC (2.29‰ vs 4.89‰, P < .001). Enterococci were the most frequent microorganism. Most patients presented complicated IE ( CC: 67.7%; HC: 69.6%; P = .66), but the rate of surgical treatment remained low (CC: 20.7%; HC: 17.3%; P = .32). The CC exhibited lower rates of in-hospital acute kidney injury (35.1% vs 44.6%; P = .036) and in-hospital (26.6% vs 36.4%; P = .016) and 1-year (37.8% vs 53.5%; P < .001) mortality. Higher logistic EuroScore, Staphylococcus aureus etiology, and complications (stroke, heart failure, and acute renal failure) were associated with in-hospital mortality in multivariable analyses (P < .05 for all). Although overall IE incidence has remained stable, the incidence of early IE has declined in recent years. The microorganism, high rate of complications, and very low rate of surgical treatment remained similar. In-hospital and 1-year mortality rates were high but progressively decreased over time.
Published: 2021

29. Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement

Author: Del Val, David, Abdel-Wahab, Mohamed, Linke, Axel, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Antonio, Herrmann, Howard C., Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C., Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Barbanti, Marco, Masson, Jean Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B., Mangione, Jose Armando, de Brito, Fabio Sandoli, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria Cristina, Lima, Valter Correa, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G., Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Mangner, Norman, Crusius, Lisa, Holzhey, David, Rodés-Cabau, Josep, Del Val, David, Abdel-Wahab, Mohamed, Linke, Axel, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Antonio, Herrmann, Howard C., Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio, Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C., Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Barbanti, Marco, Masson, Jean Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B., Mangione, Jose Armando, de Brito, Fabio Sandoli, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria Cristina, Lima, Valter Correa, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G., Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Mangner, Norman, Crusius, Lisa, Holzhey, David, and Rodés-Cabau, Josep
Abstract: BACKGROUND: Procedural improvements combined with the contemporary clinical profile of patients undergoing transcatheter aortic valve replacement (TAVR) may have influenced the incidence and outcomes of infective endocarditis (IE) following TAVR. We aimed to determine the temporal trends, characteristics, and outcomes of IE post-TAVR. METHODS: Observational study including 552 patients presenting definite IE post-TAVR. Patients were divided in 2 groups according to the timing of TAVR (historical cohort [HC]: before 2014; contemporary cohort [CC]: after 2014). RESULTS: Overall incidence rates of IE were similar in both cohorts (CC vs HC: 5.45 vs 6.52 per 1000 person-years; P = .12), but the rate of early IE was lower in the CC (2.29‰ vs 4.89‰, P < .001). Enterococci were the most frequent microorganism. Most patients presented complicated IE ( CC: 67.7%; HC: 69.6%; P = .66), but the rate of surgical treatment remained low (CC: 20.7%; HC: 17.3%; P = .32). The CC exhibited lower rates of in-hospital acute kidney injury (35.1% vs 44.6%; P = .036) and in-hospital (26.6% vs 36.4%; P = .016) and 1-year (37.8% vs 53.5%; P < .001) mortality. Higher logistic EuroScore, Staphylococcus aureus etiology, and complications (stroke, heart failure, and acute renal failure) were associated with in-hospital mortality in multivariable analyses (P < .05 for all). CONCLUSIONS: Although overall IE incidence has remained stable, the incidence of early IE has declined in recent years. The microorganism, high rate of complications, and very low rate of surgical treatment remained similar. In-hospital and 1-year mortality rates were high but progressively decreased over time.
Published: 2021

30. Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves:The TRANSIT International Project

Author: Testa, Luca, Agnifili, Mauro, Van Mieghem, Nicolas M., Tchétché, Didier, Asgar, Anita W., De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Colombo, Antonio, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, MacIej, Jagielak, Dariusz, Banning, Adrian P., Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Popolo Rubbio, Antonio, Casenghi, Matteo, Oreglia, Jacopo, De Marco, Federico, Tanja, Rudolph, McCabe, James M., Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Biondi Zoccai, Giuseppe, Bianchi, Giovanni, Sondergaard, Lars, Bedogni, Francesco, Testa, Luca, Agnifili, Mauro, Van Mieghem, Nicolas M., Tchétché, Didier, Asgar, Anita W., De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Colombo, Antonio, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, MacIej, Jagielak, Dariusz, Banning, Adrian P., Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Popolo Rubbio, Antonio, Casenghi, Matteo, Oreglia, Jacopo, De Marco, Federico, Tanja, Rudolph, McCabe, James M., Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Biondi Zoccai, Giuseppe, Bianchi, Giovanni, Sondergaard, Lars, and Bedogni, Francesco
Abstract: Background: Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in the treatment of patients with severe aortic stenosis. However, the durability of bioprostheses is still a matter of concern, and little is known about the management of degenerated TAV. We sought to evaluate the outcomes of patients with a degenerated TAV treated by means of a second TAVR. Methods: The TRANSIT is an international registry that included cases of degenerated TAVR from 28 centers. Among around 40 000 patients treated with TAVR in the participating centers, 172 underwent a second TAVR: 57 (33%) for a mainly stenotic degenerated TAV, 97 (56%) for a mainly regurgitant TAV, and 18 (11%) for a combined degeneration. Overall, the rate of New York Heart Association class III/IV at presentation was 73.5%. Results: Valve Academic Research Consortium 2 device success rate was 79%, as a consequence of residual gradient (14%) or regurgitation (7%). At 1 month, the overall mortality rate was 2.9%, while rates of new hospitalization and New York Heart Association class III/IV were 3.6% and 7%, respectively, without significant difference across the groups. At 1 year, the overall mortality rate was 10%, while rates of new hospitalization and New York Heart Association class III/IV were 7.6% and 5.8%, respectively, without significant difference across the groups. No cases of valve thrombosis were recorded. Conclusions: Selected patients with a degenerated TAV may be safely and successfully treated by means of a second TAVR. This finding is of crucial importance for the adoption of the TAVR technology in a lower risk and younger population.
Published: 2021

31. Stroke Complicating Infective Endocarditis After Transcatheter Aortic Valve Replacement

Author: del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N., Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C., Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L., Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C., Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B., Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria Cristina, Correia de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G., Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, Rodés-Cabau, Josep, del Val, David, Abdel-Wahab, Mohamed, Mangner, Norman, Durand, Eric, Ihlemann, Nikolaj, Urena, Marina, Pellegrini, Costanza, Giannini, Francesco, Gasior, Tomasz, Wojakowski, Wojtek, Landt, Martin, Auffret, Vincent, Sinning, Jan Malte, Cheema, Asim N., Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C., Testa, Luca, Won-Keun, Kim, Castillo, Juan Carlos, Alperi, Alberto, Tchetche, Didier, Bartorelli, Antonio L., Kapadia, Samir, Stortecky, Stefan, Amat-Santos, Ignacio, Wijeysundera, Harindra C., Lisko, John, Gutiérrez-Ibanes, Enrique, Serra, Vicenç, Salido, Luisa, Alkhodair, Abdullah, Livi, Ugolino, Chakravarty, Tarun, Lerakis, Stamatios, Vilalta, Victoria, Regueiro, Ander, Romaguera, Rafael, Kappert, Utz, Barbanti, Marco, Masson, Jean Bernard, Maes, Frédéric, Fiorina, Claudia, Miceli, Antonio, Kodali, Susheel, Ribeiro, Henrique B., Mangione, Jose Armando, Sandoli de Brito, Fabio, Actis Dato, Guglielmo Mario, Rosato, Francesco, Ferreira, Maria Cristina, Correia de Lima, Valter, Colafranceschi, Alexandre Siciliano, Abizaid, Alexandre, Marino, Marcos Antonio, Esteves, Vinicius, Andrea, Julio, Godinho, Roger R., Alfonso, Fernando, Eltchaninoff, Helene, Søndergaard, Lars, Himbert, Dominique, Husser, Oliver, Latib, Azeem, Le Breton, Hervé, Servoz, Clement, Pascual, Isaac, Siddiqui, Saif, Olivares, Paolo, Hernandez-Antolin, Rosana, Webb, John G., Sponga, Sandro, Makkar, Raj, Kini, Annapoorna S., Boukhris, Marouane, Gervais, Philippe, Linke, Axel, Crusius, Lisa, Holzhey, David, and Rodés-Cabau, Josep
Abstract: Background: Stroke is one of the most common and potentially disabling complications of infective endocarditis (IE). However, scarce data exist about stroke complicating IE after transcatheter aortic valve replacement (TAVR). Objectives: The purpose of this study was to determine the incidence, risk factors, clinical characteristics, management, and outcomes of patients with definite IE after TAVR complicated by stroke during index IE hospitalization. Methods: Data from the Infectious Endocarditis after TAVR International Registry (including 569 patients who developed definite IE following TAVR from 59 centers in 11 countries) was analyzed. Patients were divided into two groups according to stroke occurrence during IE admission (stroke [S-IE] vs. no stroke [NS-IE]). Results: A total of 57 (10%) patients had a stroke during IE hospitalization, with no differences in causative microorganism between groups. S-IE patients exhibited higher rates of acute renal failure, systemic embolization, and persistent bacteremia (p < 0.05 for all). Previous stroke before IE, residual aortic regurgitation ≥moderate after TAVR, balloon-expandable valves, IE within 30 days after TAVR, and vegetation size >8 mm were associated with a higher risk of stroke during the index IE hospitalization (p < 0.05 for all). Stroke rate in patients with no risk factors was 3.1% and increased up to 60% in the presence of >3 risk factors. S-IE patients had higher rates of in-hospital mortality (54.4% vs. 28.7%; p < 0.001) and overall mortality at 1 year (66.3% vs. 45.6%; p < 0.001). Surgical treatment was not associated with improved outcomes in S-IE patients (in-hospital mortality: 46.2% in surgical vs. 58.1% in no surgical treatment; p = 0.47). Conclusions: Stroke occurred in 1 of 10 patients with IE post-TAVR. A history of stroke, short time between TAVR and IE, vegetation size, valve prosthesis type, and residual aortic regurgitation determined an increased risk. The occurrence
Published: 2021

32. Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves:The TRANSIT International Project

Author: Testa, Luca, Agnifili, Mauro, Van Mieghem, Nicolas M., Tchétché, Didier, Asgar, Anita W., De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Colombo, Antonio, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, MacIej, Jagielak, Dariusz, Banning, Adrian P., Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Popolo Rubbio, Antonio, Casenghi, Matteo, Oreglia, Jacopo, De Marco, Federico, Tanja, Rudolph, McCabe, James M., Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Biondi Zoccai, Giuseppe, Bianchi, Giovanni, Sondergaard, Lars, Bedogni, Francesco, Testa, Luca, Agnifili, Mauro, Van Mieghem, Nicolas M., Tchétché, Didier, Asgar, Anita W., De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Colombo, Antonio, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, MacIej, Jagielak, Dariusz, Banning, Adrian P., Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, Van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Popolo Rubbio, Antonio, Casenghi, Matteo, Oreglia, Jacopo, De Marco, Federico, Tanja, Rudolph, McCabe, James M., Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Biondi Zoccai, Giuseppe, Bianchi, Giovanni, Sondergaard, Lars, and Bedogni, Francesco
Abstract: Background: Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in the treatment of patients with severe aortic stenosis. However, the durability of bioprostheses is still a matter of concern, and little is known about the management of degenerated TAV. We sought to evaluate the outcomes of patients with a degenerated TAV treated by means of a second TAVR. Methods: The TRANSIT is an international registry that included cases of degenerated TAVR from 28 centers. Among around 40 000 patients treated with TAVR in the participating centers, 172 underwent a second TAVR: 57 (33%) for a mainly stenotic degenerated TAV, 97 (56%) for a mainly regurgitant TAV, and 18 (11%) for a combined degeneration. Overall, the rate of New York Heart Association class III/IV at presentation was 73.5%. Results: Valve Academic Research Consortium 2 device success rate was 79%, as a consequence of residual gradient (14%) or regurgitation (7%). At 1 month, the overall mortality rate was 2.9%, while rates of new hospitalization and New York Heart Association class III/IV were 3.6% and 7%, respectively, without significant difference across the groups. At 1 year, the overall mortality rate was 10%, while rates of new hospitalization and New York Heart Association class III/IV were 7.6% and 5.8%, respectively, without significant difference across the groups. No cases of valve thrombosis were recorded. Conclusions: Selected patients with a degenerated TAV may be safely and successfully treated by means of a second TAVR. This finding is of crucial importance for the adoption of the TAVR technology in a lower risk and younger population. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04500964.
Published: 2021

33. Impact of High Body Mass Index on Vascular and Bleeding Complications After Transcatheter Aortic Valve Implantation

Author: Berti, Sergio, Bartorelli, Antonio L, Koni, Endrin, Giordano, Arturo, Petronio, Anna S, Iadanza, Alessandro, Bedogni, Francesco, Reimers, Bernard, Spaccarotella, Carmen, Trani, Carlo, Attisano, Tiziana, Sardella, Gennaro, Bonmassari, Roberto, Medda, Massimo, Sherwood, Matthew W, Tomai, Fabrizio, Navarese, Eliano P, Trani, Carlo (ORCID:0000-0001-9777-013X), Berti, Sergio, Bartorelli, Antonio L, Koni, Endrin, Giordano, Arturo, Petronio, Anna S, Iadanza, Alessandro, Bedogni, Francesco, Reimers, Bernard, Spaccarotella, Carmen, Trani, Carlo, Attisano, Tiziana, Sardella, Gennaro, Bonmassari, Roberto, Medda, Massimo, Sherwood, Matthew W, Tomai, Fabrizio, Navarese, Eliano P, and Trani, Carlo (ORCID:0000-0001-9777-013X)
Abstract: N/A
Published: 2021

34. Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves: The TRANSIT International Project

Author: Team Medisch, Circulatory Health, Testa, Luca, Agnifili, Mauro, Van Mieghem, Nicolas M, Tchétché, Didier, Asgar, Anita W, De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Colombo, Antonio, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P, Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Popolo Rubbio, Antonio, Casenghi, Matteo, Oreglia, Jacopo, De Marco, Federico, Tanja, Rudolph, McCabe, James M, Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Biondi Zoccai, Giuseppe, Bianchi, Giovanni, Sondergaard, Lars, Bedogni, Francesco, Team Medisch, Circulatory Health, Testa, Luca, Agnifili, Mauro, Van Mieghem, Nicolas M, Tchétché, Didier, Asgar, Anita W, De Backer, Ole, Latib, Azeem, Reimers, Bernhard, Stefanini, Giulio, Trani, Carlo, Colombo, Antonio, Giannini, Francesco, Bartorelli, Antonio, Wojakowski, Wojtek, Dabrowski, Maciej, Jagielak, Dariusz, Banning, Adrian P, Kharbanda, Rajesh, Moreno, Raul, Schofer, Joachim, van Royen, Niels, Pinto, Duane, Serra, Antoni, Segev, Amit, Giordano, Arturo, Brambilla, Nedy, Popolo Rubbio, Antonio, Casenghi, Matteo, Oreglia, Jacopo, De Marco, Federico, Tanja, Rudolph, McCabe, James M, Abizaid, Alexander, Voskuil, Michiel, Teles, Rui, Biondi Zoccai, Giuseppe, Bianchi, Giovanni, Sondergaard, Lars, and Bedogni, Francesco
Published: 2021

35. Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials

Author: Navarese, Eliano P., Khan, Safi U., Kolodziejczak, Michalina, Kubica, Jacek, Buccheri, Sergio, Cannon, Christopher P., Gurbel, Paul A., De Servi, Stefano, Budaj, Andrzej, Bartorelli, Antonio, Trabattoni, Daniela, Ohman, E. Magnus, Wallentin, Lars, Roe, Matthew T., James, Stefan, Navarese, Eliano P., Khan, Safi U., Kolodziejczak, Michalina, Kubica, Jacek, Buccheri, Sergio, Cannon, Christopher P., Gurbel, Paul A., De Servi, Stefano, Budaj, Andrzej, Bartorelli, Antonio, Trabattoni, Daniela, Ohman, E. Magnus, Wallentin, Lars, Roe, Matthew T., and James, Stefan
Abstract: Background: New randomized, controlled trials have become available on oral P2Y(12)inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-analysis of randomized controlled trials. Methods: We performed a network meta-analysis and direct pairwise comparison analysis of efficacy and safety outcomes from 12 randomized controlled trials including a total of 52 816 patients with acute coronary syndrome. Results: In comparison with clopidogrel, ticagrelor significantly reduced cardiovascular mortality (hazard ratio [HR], 0.82 [95% CI, 0.72-0.92]) and all-cause mortality (HR, 0.83 [95% CI, 0.75-0.92]), whereas there was no statistically significant mortality reduction with prasugrel (HR, 0.90 [95% CI, 0.80-1.01] and HR, 0.92 [95% CI, 0.84-1.02], respectively). In comparison with each other, there were no significant differences in mortality (HR prasugrel versus ticagrelor, 1.10 [95% CI, 0.94-1.29] and 1.12 [95% CI, 0.98-1.28]). In comparison with clopidogrel, prasugrel reduced myocardial infarction (HR, 0.81 [95% CI, 0.67-0.98]), whereas ticagrelor showed no risk reduction (HR, 0.97 [95% CI, 0.78-1.22]). Differences between prasugrel and ticagrelor were not statistically significant. Stent thrombosis risk was significantly reduced by both ticagrelor and prasugrel versus clopidogrel (28%-50% range of reduction). In comparison with clopidogrel, both prasugrel (HR, 1.26 [95% CI, 1.01-1.56]) and ticagrelor (HR, 1.27 [95% CI, 1.04-1.55]) significantly increased major bleeding. There were no significant differences between prasugrel and ticagrelor for all outcomes explored. Conclusions: Prasugrel and ticagrelor reduced ischemic events and increased bleeding in comparison with clopidogrel. A significant mortality reduction was observed with ticagrelor only. There was no efficacy and safety difference between prasugrel and ticagrelor.
Published: 2020
Full Text: View/download PDF

36. Impact of Glomerular Filtration Rate on the Incidence and Prognosis of New-Onset Atrial Fibrillation in Acute Myocardial Infarction

Author: Cosentino, N, Ballarotto, M, Campodonico, J, Milazzo, V, Bonomi, A, Genovesi, S, Moltrasio, M, De Metrio, M, Rubino, M, Veglia, F, Assanelli, E, Marana, I, Grazi, M, Lauri, G, Bartorelli, A, Marenzi, G, Cosentino, Nicola, Ballarotto, Marco, Campodonico, Jeness, Milazzo, Valentina, Bonomi, Alice, Genovesi, Simonetta, Moltrasio, Marco, De Metrio, Monica, Rubino, Mara, Veglia, Fabrizio, Assanelli, Emilio, Marana, Ivana, Grazi, Marco, Lauri, Gianfranco, Bartorelli, Antonio L, Marenzi, Giancarlo, Cosentino, N, Ballarotto, M, Campodonico, J, Milazzo, V, Bonomi, A, Genovesi, S, Moltrasio, M, De Metrio, M, Rubino, M, Veglia, F, Assanelli, E, Marana, I, Grazi, M, Lauri, G, Bartorelli, A, Marenzi, G, Cosentino, Nicola, Ballarotto, Marco, Campodonico, Jeness, Milazzo, Valentina, Bonomi, Alice, Genovesi, Simonetta, Moltrasio, Marco, De Metrio, Monica, Rubino, Mara, Veglia, Fabrizio, Assanelli, Emilio, Marana, Ivana, Grazi, Marco, Lauri, Gianfranco, Bartorelli, Antonio L, and Marenzi, Giancarlo
Abstract: Background: Atrial fibrillation (AF) is a frequent complication of acute myocardial infarction (AMI) and is associated with a worse prognosis. Patients with chronic kidney disease are more likely to develop AF. Whether the association between AF and glomerular filtration rate (GFR) is also true in AMI has never been investigated. Methods: We prospectively enrolled 2445 AMI patients. New-onset AF was recorded during hospitalization. Estimated GFR was estimated at admission, and patients were grouped according to their GFR (group 1 (n = 1887): GFR >60; group 2 (n = 492): GFR 60–30; group 3 (n = 66): GFR <30 mL/min/1.73 m2). The primary endpoint was AF incidence. In-hospital and long-term (median 5 years) mortality were secondary endpoints. Results: The AF incidence in the population was 10%, and it was 8%, 16%, 24% in groups 1, 2, 3, respectively (p < 0.0001). In the overall population, AF was associated with a higher in-hospital (5% vs. 1%; p < 0.0001) and long-term (34% vs. 13%; p < 0.0001) mortality. In each study group, in-hospital mortality was higher in AF patients (3.5% vs. 0.5%, 6.5% vs. 3.0%, 19% vs. 8%, respectively; p < 0.0001). A similar trend was observed for long-term mortality in three groups (20% vs. 9%, 51% vs. 24%, 81% vs. 50%; p < 0.0001). The higher risk of in-hospital and long-term mortality associated with AF in each group was confirmed after adjustment for major confounders. Conclusions: This study demonstrates that new-onset AF incidence during AMI, as well as the associated in-hospital and long-term mortality, increases in parallel with GFR reduction assessed at admission.
Published: 2020

37. Redefining the Prognostic Value of High-Sensitivity Troponin in COVID-19 Patients: The Importance of Concomitant Coronary Artery Disease

Author: Schiavone, Marco, Gasperetti, Alessio, Mancone, Massimo, Kaplan, Aaron V, Gobbi, Cecilia, Mascioli, Giosuè, Busana, Mattia, Saguner, Ardan M, Mitacchione, Gianfranco, Giacomelli, Andrea, Sardella, Gennaro, Viecca, Maurizio, Duru, Firat, Antinori, Spinello, Carugo, Stefano, Bartorelli, Antonio L, Tondo, Claudio, Galli, Massimo, Fedele, Francesco, Forleo, Giovanni B, Schiavone, Marco, Gasperetti, Alessio, Mancone, Massimo, Kaplan, Aaron V, Gobbi, Cecilia, Mascioli, Giosuè, Busana, Mattia, Saguner, Ardan M, Mitacchione, Gianfranco, Giacomelli, Andrea, Sardella, Gennaro, Viecca, Maurizio, Duru, Firat, Antinori, Spinello, Carugo, Stefano, Bartorelli, Antonio L, Tondo, Claudio, Galli, Massimo, Fedele, Francesco, and Forleo, Giovanni B
Abstract: BACKGROUND Although studies assessing cardiovascular comorbidities and myocardial injury in Coronavirus disease 2019 (COVID-19) patients have been published, no reports focused on clinical outcomes of myocardial injury in patients with and without chronic coronary syndromes (CCS) are currently available. METHODS In this study, consecutive COVID-19 patients admitted to four different institutions were screened for enrolment. Patients were divided into two groups (CCS vs. no-CCS). Association with in-hospital mortality and related predictors represented the main study outcome; myocardial injury and its predictors were deemed secondary outcomes. RESULTS A total of 674 COVID-19 patients were enrolled, 112 (16.6%) with an established history of CCS. Myocardial injury occurred in 43.8% patients with CCS vs. 14.4% patients without CCS, as confirmed by high-sensitivity cardiac troponin (hs-cTn) elevation on admission or during hospitalization. The mortality rate in the CCS cohort was nearly three-fold higher. After adjusting for disease severity, myocardial injury resulted significantly associated with in-hospital mortality in the no-CCS group but not in CCS patients. CONCLUSIONS Patients with CCS and COVID-19 showed high mortality rate. Myocardial injury may be a bystander in CCS patients and COVID-19, while in patients without known history of CCS, myocardial injury has a significant role in predicting poor outcomes.
Published: 2020

38. Safety and feasibility evaluation of planning and execution of surgical revascularisation solely based on coronary CTA and FFR CT in patients with complex coronary artery disease: study protocol of the FASTTRACK CABG study

Author: Kawashima, Hideyuki, Pompilio, Giulio, Andreini, Daniele, Bartorelli, Antonio L, Mushtaq, Saima, Ferrari, Enrico, Maisano, Francesco, Buechel, Ronny R, Tanaka, Kaoru, La Meir, Mark, De Mey, Johan, Schneider, Ulrich, Doenst, Torsten, Teichgräber, Ulf, Stone, Gregg W, Sharif, Faisal, de Winter, Robbert, Thomsen, Brian, Taylor, Charles, Rogers, Campbell, Leipsic, Jonathon, Wijns, William, Onuma, Yoshinobu, Serruys, Patrick W; https://orcid.org/0000-0002-9636-1104, Kawashima, Hideyuki, Pompilio, Giulio, Andreini, Daniele, Bartorelli, Antonio L, Mushtaq, Saima, Ferrari, Enrico, Maisano, Francesco, Buechel, Ronny R, Tanaka, Kaoru, La Meir, Mark, De Mey, Johan, Schneider, Ulrich, Doenst, Torsten, Teichgräber, Ulf, Stone, Gregg W, Sharif, Faisal, de Winter, Robbert, Thomsen, Brian, Taylor, Charles, Rogers, Campbell, Leipsic, Jonathon, Wijns, William, Onuma, Yoshinobu, and Serruys, Patrick W; https://orcid.org/0000-0002-9636-1104
Abstract: Introduction: The previously published SYNTAX III REVOLUTION trial demonstrated that clinical decision-making between coronary artery bypass graft (CABG) and percutaneous coronary intervention based on coronary CT angiography (CCTA) had a very high agreement with the treatment decision derived from invasive coronary angiography (ICA). The study objective of the FASTTRACK CABG is to assess the feasibility of CCTA and fractional flow reserve derived from CTA (FFRCT) to replace ICA as a surgical guidance method for planning and execution of CABG in patients with three-vessel disease with or without left main disease. Methods and analysis: The FASTTRACK CABG is an investigator-initiated single-arm, multicentre, prospective, proof-of-concept and first-in-man study with feasibility and safety analysis. Surgical revascularisation strategy and treatment planning will be solely based on CCTA and FFRCT without knowledge of the anatomy defined by ICA. Clinical follow-up visit including CCTA will be performed 30 days after CABG in order to assess graft patency and adequacy of the revascularisation with respect to the surgical planning based on non-invasive imaging (CCTA) with functional assessment (FFRCT) and compared with ICA. Primary feasibility endpoint is CABG planning and execution solely based on CCTA and FFRCT in 114 patients. Primary safety endpoint based on 30 day CCTA is graft assessment and topographical adequacy of the revascularisation procedure. Automatic non-invasive assessment of functional coronary anatomy complexity is also evaluated with FFRCT for functional Synergy Between percutaneous coronary intervention With Taxus and Cardiac Surgery Score assessment on CCTA. CCTA with FFRCT might provide better anatomical and functional analysis of the coronary circulation leading to appropriate anatomical and functional revascularisation, and thereby contributing to a better outcome. Ethics and dissemination: Each patient has to provide written informed consent as appr
Published: 2020

39. The SYNTAX score on its way out or … towards artificial intelligence: part II

Author: Serruys, Patrick W, Chichareon, Ply, Modolo, Rodrigo, Leaman, David M, Reiber, Johan H C, Emanuelsson, Håkan, Di Mario, Carlo, Pijls, Nico H J, Morel, Marie-Angèle, Valgimigli, Marco, Farooq, Vasim, van Klaveren, David, Capodanno, Davide, Andreini, Daniele, Bourantas, Christos V, Davies, Justin, Banning, Adrian P, Escaned, Javier, Piek, Jan J, Echavarría-Pinto, Mauro, Taylor, Charles Anthony, Thomsen, Brian, Collet, Carlos, Pompilio, Giulio, Bartorelli, Antonio L, Glocker, Ben, Dressler, Ovidiu, Stone, Gregg W, Onuma, Yoshinobu, Serruys, Patrick W, Chichareon, Ply, Modolo, Rodrigo, Leaman, David M, Reiber, Johan H C, Emanuelsson, Håkan, Di Mario, Carlo, Pijls, Nico H J, Morel, Marie-Angèle, Valgimigli, Marco, Farooq, Vasim, van Klaveren, David, Capodanno, Davide, Andreini, Daniele, Bourantas, Christos V, Davies, Justin, Banning, Adrian P, Escaned, Javier, Piek, Jan J, Echavarría-Pinto, Mauro, Taylor, Charles Anthony, Thomsen, Brian, Collet, Carlos, Pompilio, Giulio, Bartorelli, Antonio L, Glocker, Ben, Dressler, Ovidiu, Stone, Gregg W, and Onuma, Yoshinobu
Published: 2020

40. The SYNTAX score on its way out or … towards artificial intelligence: part I

Author: Serruys, Patrick W, Chichareon, Ply, Modolo, Rodrigo, Leaman, David M, Reiber, Johan H C, Emanuelsson, Håkan, Di Mario, Carlo, Pijls, Nico H J, Morel, Marie-Angèle, Valgimigli, Marco, Farooq, Vasim, van Klaveren, David, Capodanno, Davide, Andreini, Daniele, Bourantas, Christos V, Davies, Justin, Banning, Adrian P, Escaned, Javier, Piek, Jan J, Echavarría-Pinto, Mauro, Taylor, Charles Anthony, Thomsen, Brian, Collet, Carlos, Pompilio, Giulio, Bartorelli, Antonio L, Glocker, Ben, Dressler, Ovidiu, Stone, Gregg W, Onuma, Yoshinobu, Serruys, Patrick W, Chichareon, Ply, Modolo, Rodrigo, Leaman, David M, Reiber, Johan H C, Emanuelsson, Håkan, Di Mario, Carlo, Pijls, Nico H J, Morel, Marie-Angèle, Valgimigli, Marco, Farooq, Vasim, van Klaveren, David, Capodanno, Davide, Andreini, Daniele, Bourantas, Christos V, Davies, Justin, Banning, Adrian P, Escaned, Javier, Piek, Jan J, Echavarría-Pinto, Mauro, Taylor, Charles Anthony, Thomsen, Brian, Collet, Carlos, Pompilio, Giulio, Bartorelli, Antonio L, Glocker, Ben, Dressler, Ovidiu, Stone, Gregg W, and Onuma, Yoshinobu
Published: 2020

41. Infective Endocarditis Following Transcatheter Aortic Valve Replacement:Comparison of Balloon-Versus Self-Expandable Valves

Author: Regueiro, Ander, Linke, Axel, Latib, Azeem, Ihlemann, Nikolaj, Urena, Marina, Walther, Thomas, Husser, Oliver, Herrmann, Howard C., Nombela-Franco, Luis, Cheema, Asim, Le Breton, Hervé, Stortecky, Stefan, Kapadia, Samir, Bartorelli, Antonio L., Sinning, Jan Malte, Amat-Santos, Ignacio, Munoz-Garcia, Antonio J., Lerakis, Stamatios, Gutiérrez-Ibanes, Enrique, Abdel-Wahab, Mohamed, Tchetche, Didier, Testa, Luca, Eltchaninoff, Helene, Livi, Ugolino, Castillo, Juan Carlos, Jilaihawi, Hasan, Webb, John G., Barbanti, Marco, Kodali, Susheel, De Brito, Fabio S., Ribeiro, Henrique B., Miceli, Antonio, Fiorina, Claudia, Actis Dato, Guglielmo Mario, Rosato, Francesco, Serra, Vicenç, Masson, Jean Bernard, Wijeysundera, Harindra C., Mangione, Jose A., Ferreira, Maria Cristina, Lima, Valter C., Carvalho, Luis A., Abizaid, Alexandre, Marino, Marcos A., Esteves, Vinicius, Andrea, Julio C.M., Messika-Zeitoun, David, Himbert, Dominique, Kim, Won Keun, Pellegrini, Costanza, Auffret, Vincent, Nietlispach, Fabian, Pilgrim, Thomas, Durand, Eric, Lisko, John, Makkar, Raj R., Lemos, Pedro, Leon, Martin B., Puri, Rishi, San Roman, Alberto, Vahanian, Alec, Søndergaard, Lars, Mangner, Norman, Rodés-Cabau, Josep, Regueiro, Ander, Linke, Axel, Latib, Azeem, Ihlemann, Nikolaj, Urena, Marina, Walther, Thomas, Husser, Oliver, Herrmann, Howard C., Nombela-Franco, Luis, Cheema, Asim, Le Breton, Hervé, Stortecky, Stefan, Kapadia, Samir, Bartorelli, Antonio L., Sinning, Jan Malte, Amat-Santos, Ignacio, Munoz-Garcia, Antonio J., Lerakis, Stamatios, Gutiérrez-Ibanes, Enrique, Abdel-Wahab, Mohamed, Tchetche, Didier, Testa, Luca, Eltchaninoff, Helene, Livi, Ugolino, Castillo, Juan Carlos, Jilaihawi, Hasan, Webb, John G., Barbanti, Marco, Kodali, Susheel, De Brito, Fabio S., Ribeiro, Henrique B., Miceli, Antonio, Fiorina, Claudia, Actis Dato, Guglielmo Mario, Rosato, Francesco, Serra, Vicenç, Masson, Jean Bernard, Wijeysundera, Harindra C., Mangione, Jose A., Ferreira, Maria Cristina, Lima, Valter C., Carvalho, Luis A., Abizaid, Alexandre, Marino, Marcos A., Esteves, Vinicius, Andrea, Julio C.M., Messika-Zeitoun, David, Himbert, Dominique, Kim, Won Keun, Pellegrini, Costanza, Auffret, Vincent, Nietlispach, Fabian, Pilgrim, Thomas, Durand, Eric, Lisko, John, Makkar, Raj R., Lemos, Pedro, Leon, Martin B., Puri, Rishi, San Roman, Alberto, Vahanian, Alec, Søndergaard, Lars, Mangner, Norman, and Rodés-Cabau, Josep
Abstract: Background: No data exist about the characteristics of infective endocarditis (IE) post-transcatheter aortic valve replacement (TAVR) according to transcatheter valve type. We aimed to determine the incidence, clinical characteristics, and outcomes of patients with IE post-TAVR treated with balloon-expandable valve (BEV) versus self-expanding valve (SEV) systems. Methods: Data from the multicenter Infectious Endocarditis After TAVR International Registry was used to compare IE patients with BEV versus SEV. Results: A total of 245 patients with IE post-TAVR were included (SEV, 47%; BEV, 53%). The timing between TAVR and IE was similar between groups (SEV, 5.5 [1.2-15] months versus BEV, 5.3 [1.7-11.4] months; P=0.89). Enterococcal IE was more frequent in the SEV group (36.5% versus 15.4%; P<0.01), and vegetation location differed according to valve type (stent frame, SEV, 18.6%; BEV, 6.9%; P=0.01; valve leaflet, SEV, 23.9%; BEV, 38.5%; P=0.01). BEV recipients had a higher rate of stroke/systemic embolism (20.0% versus 8.7%, adjusted OR: 2.46, 95% CI: 1.04-5.82, P=0.04). Surgical explant of the transcatheter valve (SEV, 8.7%; BEV, 13.8%; P=0.21), and in-hospital death at the time of IE episode (SEV, 35.6%; BEV, 37.7%; P=0.74) were similar between groups. After a mean follow-up of 13±12 months, 59.1% and 54.6% of the SEV and BEV recipients, respectively, had died (P=0.66). Conclusions: The characteristics of IE post-TAVR, including microorganism type, vegetation location, and embolic complications but not early or late mortality, differed according to valve type. These results may help to guide the diagnosis and management of IE and inform future research studies in the field.
Published: 2019

42. Impact of fractional flow reserve derived from coronary computed tomography angiography on heart team treatment decision-making in patients with multivessel coronary artery disease: insights from the SYNTAX III REVOLUTION trial

Author: Andreini, Daniele, Modolo, Rodrigo, Katagiri, Y, Mushtaq, Saima, Plass, André, Maisano, Francesco, Folliguet, Thierry, Serruys, Patrick W, Bartorelli, Antonio L, Andreini, Daniele, Modolo, Rodrigo, Katagiri, Y, Mushtaq, Saima, Plass, André, Maisano, Francesco, Folliguet, Thierry, Serruys, Patrick W, and Bartorelli, Antonio L
Abstract: BACKGROUND: Fractional flow reserve (FFR) is a reliable tool for the functional assessment of coronary stenoses. FFR computed tomography (CT) derived (FFRCT) has shown to be accurate, but its clinical usefulness in patients with complex coronary artery disease remains to be investigated. The present study sought to determine the impact of FFRCT on heart team's treatment decision-making and selection of vessels for revascularization in patients with 3-vessel coronary artery disease. METHODS: The trial was an international, multicenter study randomizing 2 heart teams to make a treatment decision between percutaneous coronary interventions and coronary artery bypass grafting using either coronary computed tomography angiography or conventional angiography. The heart teams received the FFRCT and had to make a treatment decision and planning integrating the functional component of the stenoses. Each heart team calculated the anatomic SYNTAX score, the noninvasive functional SYNTAX score and subsequently integrated the clinical information to compute the SYNTAX score III providing a treatment recommendation, that is, coronary artery bypass grafting, percutaneous coronary intervention, or equipoise coronary artery bypass grafting-percutaneous coronary intervention. The primary objective was to determine the proportion of patients in whom FFRCT changed the treatment decision and planning. RESULTS: Overall, 223 patients were included. Coronary computed tomography angiography assessment was feasible in 99% of the patients and FFRCT analysis in 88%. FFRCT was available for 1030 lesions (mean FFRCT value 0.64±13). A treatment recommendation of coronary artery bypass grafting was made in 24% of the patients with coronary computed tomography angiography with FFRCT. The addition of FFRCT changed the treatment decision in 7% of the patients and modified selection of vessels for revascularization in 12%. With conventional angiography as reference, FFRCT assessment resulted in reclas
Published: 2019

43. [Updated SICI-GISE position paper on institutional and operator requirements for transcatheter aortic valve implantation]

Author: Tarantini, Giuseppe, Esposito, Giovanni, Musumeci, Giuseppe, Fraccaro, Chiara, Franzone, Anna, Castiglioni, Battistina, La Manna, Alessio, Limbruno, Ugo, Marchese, Alfredo, Mauro, Ciro, Rigattieri, Stefano, Tarantino, Fabio, Gandolfo, Caterina, Santoro, Gennaro, Violini, Roberto, Airoldi, Flavio, Albiero, Remo, Balbi, Manrico, Baralis, Giorgio, Bartorelli, Antonio Luca, Bedogni, Francesco, Benassi, Alberto, Berni, Andrea, Bonzani, Giulio, Bortone, Alessandro Santo, Braito, Giuseppe, Briguori, Carlo, Brscic, Elvi, Calabrò, Paolo, Calchera, Ivan, Cappelli Bigazzi, Maurizio, Caprioglio, Francesco, Castriota, Fausto, Cernetti, Carlo, Cicala, Cinzia, Cioffi, Paolo, Colombo, Antonio, Colombo, Virgilio, Contegiacomo, Gaetano, Cremonesi, Alberto, D'Amico, Maurizio, De Benedictis, Mauro, De Leo, Alessandro, Di Biasi, Maurizio, Di Girolamo, Domenico, Di Lorenzo, Emilio, Di Mario, Carlo, Dominici, Marcello, Ettori, Federica, Ferrario, Maurizio, Fioranelli, Massimo, Fischetti, Dionigi, Gabrielli, Gabriele, Giordano, Arturo, Giudice, Pietro, Greco, Cesare, Indolfi, Ciro, Leonzi, Ornella, Lettieri, Corrado, Loi, Bruno, Maddestra, Nicola, Marchionni, Niccolò, Marrozzini, Cinzia, Medda, Massimo, Missiroli, Bindo, My, Luigi, Oreglia, Jacopo Andrea, Palmieri, Cataldo, Pantaleo, Paolo, Paparoni, Saro Roberto, Parodi, Guido, Petronio, Anna Sonia, Piatti, Luigi, Piccaluga, Emanuela, Pierli, Carlo, Perkan, Andrea, Pitì, Antonino, Poli, Arnaldo, Ramondo, Angelo Bruno, Reale, Maurizio Alessandro, Reimers, Bernhard, Ribichini, Flavio Luciano, Rosso, Roberta, Saccà, Salvatore, Sacra, Cosimo, Santarelli, Andrea, Sardella, Gennaro, Satullo, Gaetano, Scalise, Filippo, Siviglia, Massimo, Spedicato, Leonardo, Stabile, Amerigo, Tamburino, Corrado, Tesorio, Tullio Nicola Maria, Tolaro, Salvatore, Tomai, Fabrizio, Trani, Carlo, Valenti, Renato, Valsecchi, Orazio, Valva, Giuseppe, Varbella, Ferdinando, Vigna, Carlo, Vignali, Luigi, Berti, Sergio, Trani, Carlo (ORCID:0000-0001-9777-013X), Tarantini, Giuseppe, Esposito, Giovanni, Musumeci, Giuseppe, Fraccaro, Chiara, Franzone, Anna, Castiglioni, Battistina, La Manna, Alessio, Limbruno, Ugo, Marchese, Alfredo, Mauro, Ciro, Rigattieri, Stefano, Tarantino, Fabio, Gandolfo, Caterina, Santoro, Gennaro, Violini, Roberto, Airoldi, Flavio, Albiero, Remo, Balbi, Manrico, Baralis, Giorgio, Bartorelli, Antonio Luca, Bedogni, Francesco, Benassi, Alberto, Berni, Andrea, Bonzani, Giulio, Bortone, Alessandro Santo, Braito, Giuseppe, Briguori, Carlo, Brscic, Elvi, Calabrò, Paolo, Calchera, Ivan, Cappelli Bigazzi, Maurizio, Caprioglio, Francesco, Castriota, Fausto, Cernetti, Carlo, Cicala, Cinzia, Cioffi, Paolo, Colombo, Antonio, Colombo, Virgilio, Contegiacomo, Gaetano, Cremonesi, Alberto, D'Amico, Maurizio, De Benedictis, Mauro, De Leo, Alessandro, Di Biasi, Maurizio, Di Girolamo, Domenico, Di Lorenzo, Emilio, Di Mario, Carlo, Dominici, Marcello, Ettori, Federica, Ferrario, Maurizio, Fioranelli, Massimo, Fischetti, Dionigi, Gabrielli, Gabriele, Giordano, Arturo, Giudice, Pietro, Greco, Cesare, Indolfi, Ciro, Leonzi, Ornella, Lettieri, Corrado, Loi, Bruno, Maddestra, Nicola, Marchionni, Niccolò, Marrozzini, Cinzia, Medda, Massimo, Missiroli, Bindo, My, Luigi, Oreglia, Jacopo Andrea, Palmieri, Cataldo, Pantaleo, Paolo, Paparoni, Saro Roberto, Parodi, Guido, Petronio, Anna Sonia, Piatti, Luigi, Piccaluga, Emanuela, Pierli, Carlo, Perkan, Andrea, Pitì, Antonino, Poli, Arnaldo, Ramondo, Angelo Bruno, Reale, Maurizio Alessandro, Reimers, Bernhard, Ribichini, Flavio Luciano, Rosso, Roberta, Saccà, Salvatore, Sacra, Cosimo, Santarelli, Andrea, Sardella, Gennaro, Satullo, Gaetano, Scalise, Filippo, Siviglia, Massimo, Spedicato, Leonardo, Stabile, Amerigo, Tamburino, Corrado, Tesorio, Tullio Nicola Maria, Tolaro, Salvatore, Tomai, Fabrizio, Trani, Carlo, Valenti, Renato, Valsecchi, Orazio, Valva, Giuseppe, Varbella, Ferdinando, Vigna, Carlo, Vignali, Luigi, Berti, Sergio, and Trani, Carlo (ORCID:0000-0001-9777-013X)
Abstract: N/A
Published: 2018

44. Outcomes of a dedicated stent in coronary bifurcations with large side branches : A subanalysis of the randomized TRYTON bifurcation study

Author: Généreux, Philippe, Kini, Annapoorna, Lesiak, Maciej, Kumsars, Indulis, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Tarantini, Giuseppe, Bettinger, Nicolas, Minalu Ayele, Girma, LaSalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., Leon, Martin B., Généreux, Philippe, Kini, Annapoorna, Lesiak, Maciej, Kumsars, Indulis, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Tarantini, Giuseppe, Bettinger, Nicolas, Minalu Ayele, Girma, LaSalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., and Leon, Martin B.
Published: 2016

45. Outcomes of a dedicated stent in coronary bifurcations with large side branches : A subanalysis of the randomized TRYTON bifurcation study

Author: Généreux, Philippe, Kini, Annapoorna, Lesiak, Maciej, Kumsars, Indulis, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Tarantini, Giuseppe, Bettinger, Nicolas, Minalu Ayele, Girma, LaSalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., Leon, Martin B., Généreux, Philippe, Kini, Annapoorna, Lesiak, Maciej, Kumsars, Indulis, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Tarantini, Giuseppe, Bettinger, Nicolas, Minalu Ayele, Girma, LaSalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., and Leon, Martin B.
Published: 2016

46. Outcomes of a dedicated stent in coronary bifurcations with large side branches : A subanalysis of the randomized TRYTON bifurcation study

Author: Généreux, Philippe, Kini, Annapoorna, Lesiak, Maciej, Kumsars, Indulis, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Tarantini, Giuseppe, Bettinger, Nicolas, Minalu Ayele, Girma, LaSalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., Leon, Martin B., Généreux, Philippe, Kini, Annapoorna, Lesiak, Maciej, Kumsars, Indulis, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Tarantini, Giuseppe, Bettinger, Nicolas, Minalu Ayele, Girma, LaSalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., and Leon, Martin B.
Published: 2016

47. Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized TRYTON bifurcation study

Author: Cardiologie, Circulatory Health, Généreux, Philippe, Kini, Annapoorna, Lesiak, Maciej, Kumsars, Indulis, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Tarantini, Giuseppe, Bettinger, Nicolas, Minalu Ayele, Girma, LaSalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., Leon, Martin B., Cardiologie, Circulatory Health, Généreux, Philippe, Kini, Annapoorna, Lesiak, Maciej, Kumsars, Indulis, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Tarantini, Giuseppe, Bettinger, Nicolas, Minalu Ayele, Girma, LaSalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., and Leon, Martin B.
Published: 2016

48. Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death

Author: Regueiro, Ander, Linke, Axel, Latib, Azeem, Ihlemann, Nikolaj, Urena, Marina, Walther, Thomas, Husser, Oliver, Herrmann, Howard C, Nombela-Franco, Luis, Cheema, Asim N, Le Breton, Hervé, Stortecky, Stefan, Kapadia, Samir, Bartorelli, Antonio L, Sinning, Jan-Malte, Amat-Santos, Ignacio, Munoz-Garcia, Antonio, Lerakis, Stamatios, Gutiérrez-Ibanes, Enrique, Abdel-Wahab, Mohamed, Tchetche, Didier, Testa, Luca, Eltchaninoff, Hélène, Livi, Ugolino, Castillo, Juan Carlos, Jilaihawi, Hasan, Webb, John G, Barbanti, Marco, Kodali, Susheel, de Brito, Fabio S, Ribeiro, Henrique B, Miceli, Antonio, Fiorina, Claudia, Dato, Guglielmo Mario Actis, Rosato, Francesco, Serra, Vicenç, Masson, Jean-Bernard, Wijeysundera, Harindra C, Mangione, Jose A, Ferreira, Maria-Cristina, Lima, Valter C, Carvalho, Luiz A, Abizaid, Alexandre, Marino, Marcos A, Esteves, Vinicius, Andrea, Julio C M, Giannini, Francesco, Messika-Zeitoun, David, Himbert, Dominique, Kim, Won-Keun, Pellegrini, Costanza, Auffret, Vincent, Nietlispach, Fabian, Pilgrim, Thomas, Durand, Eric, Lisko, John, Makkar, Raj R, Lemos, Pedro A, Leon, Martin B, Puri, Rishi, San Roman, Alberto, Vahanian, Alec, Søndergaard, Lars, Mangner, Norman, Rodés-Cabau, Josep, Regueiro, Ander, Linke, Axel, Latib, Azeem, Ihlemann, Nikolaj, Urena, Marina, Walther, Thomas, Husser, Oliver, Herrmann, Howard C, Nombela-Franco, Luis, Cheema, Asim N, Le Breton, Hervé, Stortecky, Stefan, Kapadia, Samir, Bartorelli, Antonio L, Sinning, Jan-Malte, Amat-Santos, Ignacio, Munoz-Garcia, Antonio, Lerakis, Stamatios, Gutiérrez-Ibanes, Enrique, Abdel-Wahab, Mohamed, Tchetche, Didier, Testa, Luca, Eltchaninoff, Hélène, Livi, Ugolino, Castillo, Juan Carlos, Jilaihawi, Hasan, Webb, John G, Barbanti, Marco, Kodali, Susheel, de Brito, Fabio S, Ribeiro, Henrique B, Miceli, Antonio, Fiorina, Claudia, Dato, Guglielmo Mario Actis, Rosato, Francesco, Serra, Vicenç, Masson, Jean-Bernard, Wijeysundera, Harindra C, Mangione, Jose A, Ferreira, Maria-Cristina, Lima, Valter C, Carvalho, Luiz A, Abizaid, Alexandre, Marino, Marcos A, Esteves, Vinicius, Andrea, Julio C M, Giannini, Francesco, Messika-Zeitoun, David, Himbert, Dominique, Kim, Won-Keun, Pellegrini, Costanza, Auffret, Vincent, Nietlispach, Fabian, Pilgrim, Thomas, Durand, Eric, Lisko, John, Makkar, Raj R, Lemos, Pedro A, Leon, Martin B, Puri, Rishi, San Roman, Alberto, Vahanian, Alec, Søndergaard, Lars, Mangner, Norman, and Rodés-Cabau, Josep
Abstract: IMPORTANCE: Limited data exist on clinical characteristics and outcomes of patients who had infective endocarditis after undergoing transcatheter aortic valve replacement (TAVR).OBJECTIVE: To determine the associated factors, clinical characteristics, and outcomes of patients who had infective endocarditis after TAVR.DESIGN, SETTING, AND PARTICIPANTS: The Infectious Endocarditis after TAVR International Registry included patients with definite infective endocarditis after TAVR from 47 centers from Europe, North America, and South America between June 2005 and October 2015.EXPOSURE: Transcatheter aortic valve replacement for incidence of infective endocarditis and infective endocarditis for in-hospital mortality.MAIN OUTCOMES AND MEASURES: Infective endocarditis and in-hospital mortality after infective endocarditis.RESULTS: A total of 250 cases of infective endocarditis occurred in 20 006 patients after TAVR (incidence, 1.1% per person-year; 95% CI, 1.1%-1.4%; median age, 80 years; 64% men). Median time from TAVR to infective endocarditis was 5.3 months (interquartile range [IQR], 1.5-13.4 months). The characteristics associated with higher risk of progressing to infective endocarditis after TAVR was younger age (78.9 years vs 81.8 years; hazard ratio [HR], 0.97 per year; 95% CI, 0.94-0.99), male sex (62.0% vs 49.7%; HR, 1.69; 95% CI, 1.13-2.52), diabetes mellitus (41.7% vs 30.0%; HR, 1.52; 95% CI, 1.02-2.29), and moderate to severe aortic regurgitation (22.4% vs 14.7%; HR, 2.05; 95% CI, 1.28-3.28). Health care-associated infective endocarditis was present in 52.8% (95% CI, 46.6%-59.0%) of patients. Enterococci species and Staphylococcus aureus were the most frequently isolated microorganisms (24.6%; 95% CI, 19.1%-30.1% and 23.3%; 95% CI, 17.9%-28.7%, respectively). The in-hospital mortality rate was 36% (95% CI, 30.0%-41.9%; 90 deaths; 160 survivors), and surgery was performed in 14.8% (95% CI, 10.4%-19.2%) of patients during t
Published: 2016

49. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions

Author: Généreux, Philippe, Kumsars, Indulis, Lesiak, Maciej, Kini, Annapoorna, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Lasalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., Leon, Martin B., Généreux, Philippe, Kumsars, Indulis, Lesiak, Maciej, Kini, Annapoorna, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Lasalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., and Leon, Martin B.
Published: 2015

50. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions

Author: Généreux, Philippe, Kumsars, Indulis, Lesiak, Maciej, Kini, Annapoorna, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Lasalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., Leon, Martin B., Généreux, Philippe, Kumsars, Indulis, Lesiak, Maciej, Kini, Annapoorna, Fontos, Géza, Slagboom, Ton, Ungi, Imre, Metzger, D. Christopher, Wykrzykowska, Joanna J., Stella, Pieter R., Bartorelli, Antonio L., Fearon, William F., Lefèvre, Thierry, Feldman, Robert L., Lasalle, Laura, Francese, Dominic P., Onuma, Yoshinobu, Grundeken, Maik J., Garcia-Garcia, Hector M., Laak, Linda L., Cutlip, Donald E., Kaplan, Aaron V., Serruys, Patrick W., and Leon, Martin B.
Published: 2015

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Publication Year Range

Publication Type

Database

Publisher

55 results on '"Bartorelli, Antonio"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources